What to know
- SURMOUNT-5 was a direct randomized injection comparison.
- The 6.5 percentage-point difference is an average, not an individual forecast.
- Current formulations require product-specific assessment.
The direct answer
Tirzepatide produced greater average weight reduction than semaglutide in SURMOUNT-5. That is stronger evidence than placing results from unrelated trials beside each other. It does not identify the best medicine for every person or establish that all formulations of one molecule outperform all formulations of another. The comparison belongs to the products, doses, population and follow-up actually studied.
Who entered the study
SURMOUNT-5 randomized 751 adults with obesity without type 2 diabetes. It was an open-label trial: participants and investigators knew the treatment assignment. Weekly injections were escalated to each participant’s maximum tolerated study dose, up to tirzepatide 10 or 15 mg and semaglutide 1.7 or 2.4 mg. Follow-up for the primary comparison lasted 72 weeks. Eli Lilly funded the trial. [1]
How large was the difference?
Mean estimated weight change was −20.2% with tirzepatide and −13.7% with semaglutide. The difference is 6.5 percentage points of starting weight, rather than 6.5% of the semaglutide result. Waist circumference also fell more with tirzepatide. Gastrointestinal adverse events were common in both groups, generally mild or moderate and concentrated during escalation. [1] Those averages describe a distribution; an individual can respond above or below them.
| SURMOUNT-5 factor | What was studied |
|---|---|
| Population | 751 adults with obesity, without type 2 diabetes |
| Design | Randomized, open label; 72 weeks |
| Tirzepatide | Weekly injection; maximum tolerated 10 or 15 mg |
| Semaglutide | Weekly injection; maximum tolerated 1.7 or 2.4 mg |
| Mean weight change | −20.2% vs −13.7%; source 1 |
Why older comparisons can mislead
STEP 1 tested semaglutide against placebo, rather than tirzepatide, over 68 weeks in adults without diabetes. [2] Differences in enrollment, treatment completion and statistical handling make its average unsuitable as a substitute control arm for another trial. When a comparison graphic uses two studies, check whether it labels that comparison as indirect. A larger-looking bar may partly reflect how the study was conducted.
The 2026 product landscape matters
The current Wegovy label includes oral tablets and additional injectable presentations, including a higher-dose option for some adults. [3] SURMOUNT-5 did not test every current option. Its result should not be silently relabeled as a head-to-head test against the oral product or every dose now available. A useful consultation names the exact formulation and intended indication before discussing comparative effectiveness.
Turn the result into a practical decision
Ask the prescriber how the evidence applies to your diabetes status, other conditions, treatment history and tolerability concerns. Then ask the service for a complete recurring price, medication availability and a plan if coverage changes. Better average efficacy is only useful when a clinically appropriate treatment can be continued. Keep the prescribing service separate from the medication in that decision. A membership badge and a low introductory fee do not change the trial result.
Read the comparison you are actually being offered
For a provider quote, write the product name, formulation, treatment duration and payment route on one line. If one quote is for a branded injection and the other is for a compounded vial, label that difference before comparing prices. Also distinguish an intention to prescribe from an actual prescription and an insurance check from an approved claim. These are ordinary purchasing details, but they determine whether the treatment described in the evidence is the treatment you could receive. A useful comparison remains honest when the answer is that the products or services are too different to declare a simple winner.
Sources
Research describes groups and specific study conditions. Your medical history, symptoms and treatment decisions require advice from your own qualified clinician.
